-
Healthcare AI Leader Parminder Bhatia Joins Helio Genomics Board of Directors
IRVINE, Calif., July 16, 2026 /PRNewswire/ — Helio Genomics, Inc., a commercial-stage AI-powered precision liver diagnostics company focused on improving outcomes for at-risk patients through early cancer detection, disease surveillance, and biomarker-driven precision medicine, today
-
Sparkling Sciences Obtains International INCI Certification for iPSC Exosome
Completes Kyoto University Patent Licensing Agreement TAIPEI, June 23, 2026 /PRNewswire/ — Sparkling Sciences Co., Ltd., under TOMO YUME Group, announced it has obtained international INCI certification for iPSC Exosome and completed Kyoto University’s patent licensing
-
Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Corporate Board of Directors
Board expansion strengthens governance, strategic leadership, and capital markets engagement as Immorta Bio advances toward the clinic MIAMI, May 21, 2026 /PRNewswire/ — Immorta Bio Inc., a scientific longevity company focused on Treating Diseases of Aging and Treating
-
TheWell Bioscience Launches Universal Xeno-Free Organoid Medium to Standardize Workflows and Reduce Costs
MONMOUTH JUNCTION, N.J., May 19, 2026 /PRNewswire/ — TheWell Bioscience, a biotechnology company pioneering advanced 3D cell culture technologies, today announced the launch of its RocketCell™ Organoid Xeno-Free Essential-Core Medium, a chemically defined, universal foundation medium
-
Brain-Body Therapy Pledges $100,000 to Fund Dr. Andrew Sherwood’s Research Project at Duke University
Gift deepens the scientific foundation of the app, whose model was informed by Dr. Sherwood’s decades of research on exercise and mental health LOS ANGELES, May 19, 2026 /PRNewswire/ — Brain-Body Therapy, (https://www.brain-bodytherapy.com/), a groundbreaking mental
-
Helio Genomics Announces Strategic Commercial Partnership with Syneos Health® to Accelerate Nationwide Adoption of HelioLiver™, A Breakthrough AI-Powered Blood Test for Early Liver Cancer Detection
Syneos Health’s proven commercialization expertise to engage healthcare providers and expand access to HelioLiver™ for high-risk patients in the United States IRVINE, Calif., May 19, 2026 /PRNewswire/ — Helio Genomics, a leading AI-powered TechBio company focused
-
InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors
SOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch
-
Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™, a Multi-Analyte Blood Test, Over Ultrasound for Early Detection of Hepatocellular Carcinoma
Prospective multicenter trial shows HelioLiver™ detects more, early hepatocellular carcinoma than abdominal ultrasound for high-risk patients with cirrhosis IRVINE, Calif., May 6, 2026 /PRNewswire/ — Helio Genomics, an AI-powered TechBio company focused on early cancer detection,
-
Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility
Recent Milestones Aim to Bring a New Category of Care to One of Veterinary Medicine’s Largest Unmet Needs Gallant granted eligibility for expanded conditional approval by FDA-CVM for canine osteoarthritis (OA) stem cell therapy; targeting
-
Molecular Instruments & Empire Genomics Launch NISH Powered by HCR™ Pro: The Largest Ready-to-Use, Fully Automated ISH Library, Exclusively Available Worldwide on NeoPATH Pro
LOS ANGELES and BUFFALO, N.Y., May 5, 2026 /PRNewswire/ — Empire Genomics, a Biocare Medical company, and Molecular Instruments® (MI), founded by the inventor of HCR™ technology, today launched NISH (Neo in situ hybridization) —